Legend Biotech Corp
LEGN Nasdaq
SEC CIK 1801198
Follow Legend Biotech
Weekly email: filings, results
Revenue, last quarter
$306.4M
+64.3% vs same quarter last year
Net income
−$30.8M
−217.2% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$12.2M
+85.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1B | −$296.8M |
| FY24 | $627.2M | −$177M |
| FY23 | $285.1M | −$518.3M |
| FY22 | $117M | −$446.3M |
| FY21 | $68.8M | −$403.6M |
| FY20 | $75M | −$266.4M |
| FY19 | $60M | −$101.6M |
| FY18 | $49.1M | −$2.8M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 61.4% | −13.3% | −28.8% |
| FY24 | 65.5% | −49.3% | −28.2% |
| FY23 | 49.4% | −185.2% | −181.8% |
| FY22 | 44.1% | - | −381.5% |
| FY21 | 100% | - | −586.4% |
| FY20 | 100% | - | −355.2% |
| FY19 | - | - | −169.4% |
| FY18 | - | - | −5.7% |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$128.8M |
| FY24 | −$158.1M |
| FY23 | −$413.4M |
| FY22 | −$222.2M |
| FY21 | −$240.7M |
| FY20 | −$249.3M |
| FY19 | −$109.8M |
| FY18 | $286.7M |
| FY17 | - |
- Legend Biotech
- Healthcare median
Show the numbers
| Year | Legend Biotech | Healthcare median |
|---|---|---|
| FY25 | −28.8% | −30.6% |
| FY24 | −28.2% | −47% |
| FY23 | −181.8% | −58% |
| FY22 | −381.5% | −80.4% |
| FY21 | −586.4% | −71.9% |
| FY20 | −355.2% | −62.2% |
| FY19 | −169.4% | −46.3% |
| FY18 | −5.7% | −49.6% |
| FY17 | - | −45.9% |